U.S. Stem Cell, Inc. is a biotechnology company, which focuses on the discovery, development, and subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its product MyoCell, deals with the clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company was founded by Howard J. Leonhardt and Robert D. Lashinski on August 12, 1999 and is headquartered in Sunrise, FL.
Company profile
Ticker
USRM
Exchange
Website
CEO
Miguel Tomás
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
PPD • IQVIA • PRA Health Sciences • Charles River Laboratories International • Syneos Health • Icon • Medpace • Incyte • Zymergen • OmniAb ...
Former names
BIOHEART, INC.
SEC CIK
Corporate docs
Subsidiaries
U.S. Stem Cell Clinic, LLC • Regenerative Wellness Clinic, LLC • U.S. Stem Cell Clinic of The Villages LLC ...
IRS number
650945967
USRM stock data
Latest filings (excl ownership)
NT 10-Q
Notice of late quarterly filing
15 May 23
10-K
2022 FY
Annual report
14 Apr 23
NT 10-K
Notice of late annual filing
31 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
22 Aug 22
NT 10-Q
Notice of late quarterly filing
15 Aug 22
UPLOAD
Letter from SEC
1 Aug 22
CORRESP
Correspondence with SEC
27 Jul 22
UPLOAD
Letter from SEC
27 Jun 22
Latest ownership filings
Financial summary
Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 5.13 k | 5.13 k | 5.13 k | 5.13 k | 5.13 k | 5.13 k |
Cash burn (monthly) | 8.34 k | 2.86 k | 188.87 k | 238.16 k | 14.36 k | 25.40 k |
Cash used (since last report) | 132.25 k | 45.26 k | 2.99 mm | 3.78 mm | 227.58 k | 402.75 k |
Cash remaining | -127.11 k | -40.13 k | -2.99 mm | -3.77 mm | -222.45 k | -397.62 k |
Runway (months of cash) | -15.2 | -14.1 | -15.8 | -15.8 | -15.5 | -15.7 |